AD/PD 2022 | Targeting the AMPK cascade to rescue mitochondrial dysfunctions in Alzheimer’s disease

Mounia Chami, PhD-HDR, Institute of Molecular and Cellular Pharmacology (IPMC), Sophia-Antipolis, France, discusses an ongoing study investigating the molecular mechanisms underlying mitochondrial dysfunction in Alzheimer’s disease. The AMPK cascade, which is known to be implicated in mitophagy and dysregulated in Alzheimer’s disease, was targeted through pharmacological and genetic approaches. By activating this pathway, it was possible to reverse many symptoms of Alzheimer’s disease – including amyloid-β accumulation, tau phosphorylation, and cognitive deficits. This interview took place at the AD/PD™ 2022 Conference in Barcelona, Spain.